Absci (NASDAQ:ABSI) Posts Earnings Results, Meets Estimates

Absci (NASDAQ:ABSI) released its earnings results on Thursday. The company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19), FiscalAI reports. Absci had a negative return on equity of 62.33% and a negative net margin of 4,113.68%.The business had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $1.39 million.

Here are the key takeaways from Absci’s conference call:

• ABS-201 is on track—blinded safety/tolerability/PK data from the SAD cohorts is expected next month, with an interim 13?week proof?of?concept readout in H2 2026 and a full 26?week POC in early 2027, and PK modeling supports roughly 2–3 injections over six months.
• Management projects a >$25 billion U.S. total available market for androgenetic alopecia and cites a target profile (~35 hairs/cm² similar to high?dose oral minoxidil) that could expand the market, but these figures are forward?looking and survey?based.
• The pipeline is expanding within prolactin biology with the addition of ABS-202, an anti?prolactin receptor antibody aimed at inflammatory/immune indications, signaling strategic focus on a franchise approach beyond AGA and endometriosis.
• Absci is de?emphasizing oncology and will stop internal funding for ABS?301 and ABS?501, narrowing therapeutic diversity and concentrating resources on ABS?201 and prolactin?focused programs.
• Financials show $125.7M in cash and marketable securities at March 31, 2026 with management saying runway into H1 2028, Q1 R&D spend rose to $19.3M, and the company is pursuing non?dilutive partnerships and AI?driven efficiency gains.

Absci Trading Down 3.4%

NASDAQ ABSI traded down $0.20 during trading hours on Thursday, hitting $5.75. 6,413,573 shares of the company’s stock were exchanged, compared to its average volume of 5,095,980. The stock has a 50-day simple moving average of $3.29 and a 200 day simple moving average of $3.31. Absci has a 1-year low of $2.24 and a 1-year high of $6.24. The firm has a market cap of $893.84 million, a price-to-earnings ratio of -6.76 and a beta of 2.36.

Insider Buying and Selling

In other news, insider Andreas Busch acquired 100,000 shares of Absci stock in a transaction on Thursday, March 12th. The stock was purchased at an average price of $2.29 per share, with a total value of $229,000.00. Following the completion of the purchase, the insider owned 421,446 shares of the company’s stock, valued at approximately $965,111.34. The trade was a 31.11% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 10.49% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Absci

A number of hedge funds have recently added to or reduced their stakes in ABSI. AQR Capital Management LLC grew its stake in Absci by 279.4% in the first quarter. AQR Capital Management LLC now owns 55,538 shares of the company’s stock valued at $139,000 after acquiring an additional 40,901 shares during the period. Goldman Sachs Group Inc. grew its stake in Absci by 17.5% in the first quarter. Goldman Sachs Group Inc. now owns 314,858 shares of the company’s stock valued at $790,000 after acquiring an additional 46,975 shares during the period. Woodline Partners LP grew its stake in Absci by 32.9% in the first quarter. Woodline Partners LP now owns 1,391,245 shares of the company’s stock valued at $3,492,000 after acquiring an additional 344,270 shares during the period. Geode Capital Management LLC grew its stake in Absci by 22.5% in the second quarter. Geode Capital Management LLC now owns 2,445,450 shares of the company’s stock valued at $6,286,000 after acquiring an additional 448,984 shares during the period. Finally, Creative Planning grew its stake in Absci by 145.4% in the second quarter. Creative Planning now owns 46,882 shares of the company’s stock valued at $120,000 after acquiring an additional 27,775 shares during the period. Institutional investors and hedge funds own 52.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on ABSI. Morgan Stanley cut Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 target price for the company. in a research note on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a research note on Monday, April 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 target price on shares of Absci in a research note on Wednesday, March 25th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Absci currently has an average rating of “Hold” and an average price target of $6.44.

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.